This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Volume: 387, Issue: 4, Pages: 321 - 331
Published: Jul 27, 2022
Abstract
Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.In this phase 2 trial, we randomly assigned adults with...
Paper Details
Title
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
Published Date
Jul 27, 2022
Volume
387
Issue
4
Pages
321 - 331
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.